Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial

Phase 2sabizabulindaraxonrasibPositive

AI Analysis

Summary

Veru announced positive preclinical data for oral sabizabulin demonstrating potent anticancer activity and ability to overcome daraxonrasib resistance in pancreatic cancer, supporting advancement into a planned Phase 2 clinical trial. The compound previously showed good safety and promising efficacy in a Phase 1b/2 study of 80 metastatic prostate cancer patients.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Positive preclinical data showing sabizabulin can overcome drug resistance to daraxonrasib with IC50=18.2nM in resistant pancreatic cancer cell lines; planned Phase 2 trial advancement

Importance:6/10

Sentiment:

0.70

preclinical datadrug resistancepancreatic cancerPhase 2 advancementoral formulation

Related Companies

$RVMD $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 8, 2026 12:17 PM

Read Original